Olympus Partners completed the acquisition of PAI Pharma.

Olympus Partners, a private equity firm focused on providing equity capital for middle market management buyouts and for growing companies, completed the acquisition of PAI Pharma, a developer, manufacturer and distributor of generic oral liquids in both ready-to-dose cups and bottles in the United States. Financial terms were not disclosed. "PAI has been at the forefront of manufacturing better-targeted suspensions, oral solutions, and liquids across a variety of packaging formats for nearly 50 years. We are excited to work with a team that has a track record as impressive as PAI as they continue their mission of delivering medications safely, reliably, and affordably," Griffin Barstis, Olympus Partner.